Eagle Pharmaceuticals Inc (EGRX)

Trade EGRX now with
1/13/2020 6:56:13 AM Eagle Pharma To Develop Dantrolene Sodium For Treatment Of Alzheimer's Disease In Collaboration With University Of Penn
1/9/2020 6:54:55 AM Eagle Pharma Resubmits NDA To FDA For RYANODEX For Treatment Of Exertional Heat Stroke In Addition To Body Cooling
1/7/2020 7:24:04 AM Tyme And Eagle Pharma Announce Strategic Collaboration To Advance Oral SM-88 For Patients With Cancer
1/6/2020 6:54:14 AM Eagle, NorthShore University To Study Dantrolene Sodium For Treatment Of Concussion,Other Traumatic Brain Injury
12/16/2019 6:52:21 AM Eagle Pharma: FDA Grants Orphan Drug Designation For RYANODEX For The Treatment Of Organophosphate Exposure
12/9/2019 6:53:27 AM Eagle Pharma Begins Dosing In Pilot Study For Novel Estrogen Receptor Antagonist Product Candidate
11/14/2019 6:51:42 AM Eagle Pharmaceuticals Announces Departure Of Douglas Braunstein From Board
11/12/2019 6:56:27 AM Eagle Pharma Q3 Net Loss $2.4 Ln Or $0.17/Shr Vs Income Of $14.0 Mln Or $0.91/Shr Last Year
8/5/2019 6:55:17 AM Eagle Pharma Says Clinical Development Plan To Support The Submission Of NDA For Innovative Fulvestrant Formulation
11/27/2018 6:54:59 AM Eagle Pharma Announces Positive Results Of Pre-clinical Study Conducted To Evaluate Effects Of RYANODEX In ARS
11/1/2018 6:51:23 AM Eagle Pharmaceuticals Q3 EPS $0.91 And Adjusted Non-GAAP EPS $1.18
10/30/2018 7:22:00 AM Eagle Pharmaceuticals Begins $50 Mln Accelerated Share Repurchase
10/3/2018 7:02:39 AM Eagle Enters Agreement With USAMRICD To Evaluate Neuroprotective Effects Of RYANODEX Secondary To Nerve Agent Exposure
9/26/2018 4:35:17 PM Eagle Pharma Appoints David Pernock As Chief Operating Officer
8/7/2018 6:53:29 AM Eagle Pharmaceuticals Q2 Net Income $2.7 Mln Or $0.17/Shr Vs $4.5 Mln Or $0.28/Shr Last Year
7/9/2018 7:03:02 AM FDA Grants Eagle Pharma Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine Hydrochloride Injection)
7/3/2018 8:32:06 AM Eagle Pharmaceuticals Announces New Patent Issued For BENDEKA